UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ Pricing Sends Clear Message To Others
Executive Summary
The UK competition authority has fined Pfizer and Flynn Pharma a total of £90m for charging “excessive and unfair” prices for phenytoin sodium capsules; Pfizer has said it will appeal. With an earlier CMA decision to impose a hefty fine on GlaxoSmithKline for its part in a pay-for-delay deal, companies should pay careful consideration to any competition issues raised by their pricing strategies for marketed drugs.
You may also be interested in...
Court Ruling On Pfizer Price Hikes Could Delay Other Investigations, Warns UK Competition Authority
Ongoing Investigations into drug price increases could be at risk following a tribunal ruling in the UK phenytoin sodium case, according to the Competition and Markets Authority, which is considering an appeal against the judgment.
Pharma Faces More Probes On Generic Price Hikes in UK
As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.
Pharma Faces More Probes On Generic Price Hikes in UK
As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.